Ibandronska Kislina Synthon (Ibandronic Acid)

Ibandronic acid binds to bone mineral surfaces and is released during osteoclast‑mediated bone resorption. It inhibits the enzyme farnesyl pyrophosphate synthase in the mevalonate pathway, which disrupts osteoclast function and leads to decreased bone breakdown, thereby improving bone density over time.

The specific dose and dosing schedule of Ibandronska Kislina Synthon are determined by the prescribing healthcare professional based on the patient’s condition, renal function, and other clinical factors. Patients should follow the prescriber’s instructions and not alter the dose on their own.

The safety of ibandronic acid in pregnancy and lactation has not been established. It is generally advised to avoid use during pregnancy and while breastfeeding unless the potential benefit justifies the potential risk, and this decision should be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Ibandronic acid is similar to other bisphosphonates such as alendronate and risedronate in its mechanism of inhibiting osteoclast activity, but it is often administered less frequently (e.g., monthly or quarterly) and may have a different side‑effect profile. Choice of agent depends on patient preference, renal function, and physician assessment.

Store the product at room temperature, below 25 °C, in its original packaging. Keep it away from moisture, heat, and direct sunlight to maintain stability and potency throughout its shelf life.

The medication is taken orally with a full glass of water on an empty stomach, preferably first thing in the morning. Patients should remain upright for at least 30 minutes after ingestion and avoid eating or drinking anything else during that time to reduce esophageal irritation.

Serious risks, although rare, include osteonecrosis of the jaw, atypical femur fractures, and severe esophagitis. Patients should report persistent jaw pain, swelling, or exposed bone, as well as any new thigh or groin pain, to their healthcare provider promptly.

Individuals with severe renal impairment (e.g., creatinine clearance below 30 mL/min), known hypersensitivity to ibandronic acid, or active esophageal disorders should avoid using this product. Additionally, patients unable to remain upright for 30 minutes after dosing should not take oral ibandronate.